Larvol Delta - A-Phase-3-Study-to-Evaluate-the-Efficacy-and-Safety-of-Intravitreal-KSI101-in-Participants-With-Macular-Edema-Secondary-to-Inflammation-MESI--PEAK

SIRPant-M (SI-101) - SIRPant Immunotherap

tabirafusp alfa (KSI-101) - Kodiak Sciences

http://clinicaltrials.gov/ct2/show/NCT06990399

Sep 11, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next